Back to Journals » Biologics: Targets and Therapy » Volume 2 » Issue 4

Rituximab in the treatment of non-Hodgkin’s lymphoma

Authors Hauptrock B, Hess G

Published 5 December 2008 Volume 2008:2(4) Pages 619—633

DOI https://doi.org/10.2147/BTT.S3235

Review by Single-blind

Peer reviewer comments 4

Beate Hauptrock, Georg Hess

Hematology/Oncology, Johannes Gutenberg-University, Mainz, Germany

Abstract: Besides traditional cytostatic drugs the introduction of monoclonal antibodies has substantially influenced current treatment concepts of non-Hodgkin’s lymphoma (NHL).  Rituximab, a monoclonal anti-CD20 chimeric antibody, now has been widely evaluated in the various B-cell lymphatic neoplasms. Large phase III studies helped to prove the value of this drug in follicular lymphoma as part of induction or relapse treatment as well as maintenance treatment. The addition of rituximab to the well established CHOP regimens has increased achievable cure rates in diffuse large cell lymphoma, and this combination is now accepted worldwide as standard of care. Although conflicting results are available, rituximab is widely used for the treatment of mantle cell lymphoma. For the less frequent lymphoma entities phase 2 studies show a considerable efficiency for most of these B-NHL variants. Current research focuses on combined chemoimmunotherapy approaches, optimization of dosing regimens, and combination with novel agents.

Keywords: non-Hodgkin’s lymphoma, rituximab, monoclonal-antibody, targeted therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]